Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 18, 2021

Primary Completion Date

April 14, 2023

Study Completion Date

April 14, 2023

Conditions
Pancreatic Cancer Stage IV
Interventions
DRUG

CBP501 (16)

16 mg/m2

DRUG

CBP501 (25)

25 mg/m2

DRUG

Cisplatin

60mg/m2

DRUG

Nivolumab

240 mg

Trial Locations (20)

19713

Medical Oncology Hematology Consultants, PA, Newark

22205

Virginia Cancer Specialists, PC, Arrington

45245

Oncology Hematology Care, Inc., Cincinnati

48109

University of Michigan hospital, Ann Arbor

55404

Minnesota oncology Hematology, P.A., Minneapolis

60005

Illinois Cancer Specialists, Arlington Heights

70121

Ochsner Clinic Foundation, Los Angeles

75071

Texas Oncology- McKinney, McKinney

75230

Mary Crowley Medical Research Center, Dallas

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology-Northeast Texas, Tyler

76508

Baylor Scott & White Medical Center, Temple

78217

Texas Oncology-San Antonio Northeast, San Antonio

78503

Texas Oncology-McAllen South Second Street, McAllen

78705

Texas Oncology-Austin Midtown, Austin

80045

University of Colorado Cancer Center, Aurora

85704

Arizona Oncology Associates, PC-HOPE, Tucson

89052

James D Sanchez, Henderson

98405

Northwest Medical Specialties, Tacoma

98684

Northwest Cancer Specialists, P.C., Vancouver

All Listed Sponsors
lead

CanBas Co. Ltd.

INDUSTRY

NCT04953962 - Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter